Cellectis Cancer Trials Suspended by U.S. FDA After Fatality

Cellectis SA said the U.S. Food and Drug Administration suspended two studies for an experimental treatment for blood cancers after the company reported the death of a patient.

The agency stopped the trials after a 78-year-old male died on the ninth day after he was given Cellectis’s treatment, called UCART123, the Paris-based company said in a statement. The patient suffered from cytokine release syndrome, a dangerous immune system response, as well as capillary leak syndrome, in which large volumes of plasma and other blood components leak out of the blood vessels.

A patient in a different trial, a 58-year-old ...